(NASDAQ: GTHX) G1 Therapeutics's forecast annual revenue growth rate of 17.99% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.64%.
G1 Therapeutics's revenue in 2024 is $84,041,000.On average, 4 Wall Street analysts forecast GTHX's revenue for 2024 to be $3,681,132,740, with the lowest GTHX revenue forecast at $3,225,761,825, and the highest GTHX revenue forecast at $4,192,444,744. On average, 4 Wall Street analysts forecast GTHX's revenue for 2025 to be $5,091,789,232, with the lowest GTHX revenue forecast at $3,549,906,449, and the highest GTHX revenue forecast at $5,941,780,087.
In 2026, GTHX is forecast to generate $7,360,435,632 in revenue, with the lowest revenue forecast at $4,082,131,009 and the highest revenue forecast at $9,426,334,797.